MedTrace Logo

The Clinical Role of Intravenous Glutamine in Trauma Patients Receiving Enteral Nutrition

NCT01240291 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2012-05-24

No results posted yet for this study

Summary

The purpose of this trial is to investigate if pharmacologically safe dose intravenous glutamine dipeptide supplementation to multiple trauma patients receiving enteral nutrition is associated with improved clinical outcomes in terms of decreased organ dysfunction, infectious complications, and other secondary outcomes

Conditions

  • Multiple Trauma
  • Critically Ill

Interventions

DIETARY_SUPPLEMENT

Dipeptiven

Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.

DIETARY_SUPPLEMENT

normal saline

0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks

Sponsors & Collaborators

  • Royal Brisbane and Women's Hospital

    lead OTHER_GOV

Principal Investigators

  • Jeffrey Lipman, MBBCh, MD · Royal Brisbane & Women's Hpsoital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-12-31
Completion
2013-06-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240291 on ClinicalTrials.gov